From Nasdaq: 2025-06-01 21:28:00

Nxera Pharma Co., Ltd. has reached a development milestone in its collaboration with Eli Lilly and Co. focused on diabetes and metabolic diseases, resulting in an undisclosed payment to Nxera. The payment is expected in the third quarter of 2025. Nxera and Lilly partnered in 2022 to utilize Nxera’s drug design capabilities and Lilly’s expertise. Nxera could receive up to US$694 million in milestones and royalties on global sales as part of the agreement. Lilly will now take over development and commercialization responsibilities. For more health news, visit rttnews.com. (Source: RTTNews)



Read more at Nasdaq: Nxera Pharma Reaches Key Milestone In Lilly Partnership For Diabetes & Metabolic Disease Research